FRX News 94.58 06/16/2014 04:55:51 Forest Laboratories (FRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 94.58 $FRX

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.

Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of Forest's securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of its securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis plc (NYSE:ACT) will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering.

Consent Expiry Extensions, Collaborations, Grants, Conference Presentations, and FDA Approvals - Analyst Notes on Forest Laboratories, Intuitive Surgical, Horizon Pharma, Cubist and BDSI
PR Newswire - Thu Jun 12, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), Horizon Pharma Inc (NASDAQ: HZNP), Cubist Pharmaceuticals Inc (NASDAQ: CBST) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3640-100free.

Arrhythmias - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3k97mr/arrhythmias) has announced the addition of the "Arrhythmias - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Gilead Sciences - Forest Laboratories - Orion - Compugen - SciFluor For more information visit http://www.researchandmarkets.com/research/3k...rrhythmias

Forest Laboratories plans to continue marketing both NAMENDA TABLETS and once-daily NAMENDA XR up to autumn of 2014
M2 - Wed Jun 11, 7:12AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Tuesday that it will continue to market both its NAMENDA (memantine HCl) 5 mg and 10 mg tablets and once-daily NAMENDA XR (memantine HCl) extended-release capsules through to the the autumn of this year.

Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.

Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--

Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.

2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain

Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations" to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.

Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...

Active Stocks Technical Coverage -- Research on Forest Laboratories, NII Holdings, Endo Intl., and Aramark
PR Newswire - Mon Jun 02, 6:40AM CDT
The trading session on Friday, May 30, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,717.17, up 0.11% and the NASDAQ Composite closed at 4,242.62, down 0.13%. The S&P 500 finished the day 0.18% higher at 1,923.57. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), NII Holdings Inc. (NASDAQ: NIHD), Endo International PLC (NASDAQ: ENDP) and Aramark (NYSE: ARMK). Free technical research on FRX, NIHD, ENDP and ARMK can be downloaded upon signing up at:

Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The  Science Translational Medicine  journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories  under the brand name Celexa, as a potential way to help slow down the development of...

Forest Laboratories, Inc. Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Business Wire - Fri May 30, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.

Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...

Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 128

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 197

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 107

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 37

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 237

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading

Top 5 Most Recently Viewed Articles

Tarkett Updates on Voting Rights and Share Capital Structure

Updated Category News Views 57

Tarkett's Current Voting Rights and Share Capital The information regarding Tarkett’s share capital and the total number of voting rights reflects vital details for investors and stakeholders. As of the designated date, Tarkett boasts a significant total number of shares that contribute to its economic activities. Understanding Voting Rights in Tarkett As a significant...

Continue Reading
Quiddity Engineering Welcomes Ryan Quinn as New GM in Texas

Updated Category News Views 267

Quiddity Engineering Introduces Ryan Quinn, PE, as General Manager Quiddity Engineering is thrilled to share the news of Ryan Quinn, PE, joining the team as the General Manager for its Central Texas region. This appointment signifies a key strategic move for the organization, as Ryan brings over 18 years of invaluable experience in the consulting engineering landscape....

Continue Reading
Pure Roofing Unveils Innovative Office Space Focused on Growth

Updated Category News Views 206

Pure Roofing Launches New Office to Elevate Employee Culture Pure Roofing has recently expanded by opening a new office, reflecting a commitment to employee well-being and community engagement. Featuring a unique design that includes an indoor basketball court, this innovative space aims to enhance teamwork, productivity, and wellness among staff. The establishment of...

Continue Reading
Crown Point Energy Reports Q3 Financial Performance Highlights

Updated Category News Views 207

Crown Point Energy Announces Financial Results for Q3 Crown Point Energy Inc. recently shared its operating and financial results for the period ending September 30, 2024. These insights reflect the company’s performance amidst varied market conditions. Financial Overview of Q3 2024 In Q3 2024, Crown Point faced several challenges but also solid achievements: Reported a...

Continue Reading
Empowering Financial Innovation: Semifinalists of 2024 Edition

Updated Category News Views 125

Milken-Motsepe Prize in FinTech Announces Semifinalists The Milken Institute and the Motsepe Foundation have revealed the 10 standout teams that have advanced to the Semifinalist Round of the prestigious Milken-Motsepe Prize in FinTech, each securing $100,000 in funding to fuel their innovative projects. Driving Financial Inclusion Through Innovation This esteemed prize...

Continue Reading